Archimedes announces positive NasalFent results

UK-based firm Archimedes Pharma has announced the first positive phase III clinical trial results for its novel fentanyl citrate nasal spray, NasalFent.

The spray has been developed to provide patients with rapid, convenient and effective treatment for breakthrough cancer pain.

Archimedes said the product met its primary efficacy endpoint and showed significant difference in pain within five minutes of dosing.

Furthermore, these improvements in pain were maintained throughout the episode.

The pivotal 043 phase III clinical study used the Summary of Pain Intensity Difference at 30 minutes to assess the drug in comparison to placebo.

Richard de Souza, chief executive officer of Archimedes, said: “We are pleased with the study results which position NasalFent – the first real intranasal form of fentanyl – as a product that redefines the standard of care for patients suffering with breakthrough cancer pain.”

He added the this achievement validates the companies business model of building a rapid-growing commercial organisation to commercialise its product pipeline built around its proprietary nasal technology.

Last month, Archimedes announced the launch of Zibor (bemiparin sodium) to expand its critical care portfolio in the UK.

The second-generation low molecular weight heparin has been licensed for post-operative initiation of thromboprophylaxis general and orthopaedic surgery patients.